Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

Statistics in Medicine

Volumn 21, Issue 11, 2002, Pages 1575-1600

  Deeks, Jonathan J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Binary data; Meta analysis; Odds ratio; Randomized controlled trials; Risk difference; Risk ratio

Indexed keywords

ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; EMPIRICISM; HUMAN; MATHEMATICAL ANALYSIS; META ANALYSIS; OUTCOMES RESEARCH; PREDICTION; REVIEW; RISK ASSESSMENT; SAMPLING; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CLINICAL TRIALS; DYSPEPSIA; HELICOBACTER PYLORI; HUMANS; IMMUNIZATION; MENINGITIS; META-ANALYSIS; ODDS RATIO; PAIN; POLYSACCHARIDES, BACTERIAL;

EID: 0037098201     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1188     Document Type: Article

References (46)

1. Statistical Methods in Cancer Research
2. Down with odds ratios!
3. When can odds ratios mislead?
4. Odds ratios revisited
5. Odds ratios revisited
6. Heterogeneity and statistical significance in meta-analysis: An empirical study of 125 meta-analyses
7. Odds ratios revisited
8. Choice of effect measure for epidemiological data
9. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis
10. Estimation of a common effect parameter from sparse follow-up data
11. sbe24: Metan - An alternative meta-analysis command
12. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis (Cochrane Review)
13. Eradication of Helicobacter Pylori for non-ulcer dyspepsia (Cochrane Review)
14. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
15. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials
16. Eradication of Helicobacter Pylori for non-ulcer dyspepsia (Cochrane Review)
17. Single dose oral aspirin for acute pain (Cochrane review)
18. Lamotrigine add-on for drug-resistant partial epilepsy (Cochrane review)
19. A graphical display useful for meta-analysis
20. An assessment of clinically useful measures of the consequences of treatment
21. The effects of information framing on the practices of physicians
22. Large trials with simple protocols: Indications and contraindications
23. Who benefits from medical interventions? Treating low risk patients can be a high risk strategy
24. An evidence based approach to individualising treatment
25. The number needed to treat: A clinically useful measure of treatment effect
26. Cholesterol lowering and mortality: The importance of considering initial level of risk
27. Choosing an appropriate dichotomous effect measure for meta-analysis: Empirical evidence of the appropriateness of the odds ratio and relative risk
28. Effect measures for meta-analysis of trials with binary outcomes
29. The relation between treatment benefit and underlying risk in meta-analysis
30. Importance of trends in the interpretation of an overall odds ration in the meta-analysis of clinical trials
31. The population risk as an explanatory variable in research synthesis of clinical trials
32. Investigating underlying risk as a source of heterogeneity in meta-analysis
33. Variation in baseline risk as an explanation of heterogeneity in meta-analysis
34. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials
35. Odds ratios should be avoided when events are common
36. Misunderstandings about the effects of race and sex on physician's referrals for cardiac catheterization
37. General practitioner's perceptions of the route to evidence based medicine: A questionnaire survey
38. Indexes of contrast and quantitative significance for comparisons of two groups
39. Clinically useful measures of effects in binary analyses of randomized trials
40. Comment
41. Statistical aspects of the analysis of data from retrospective studies in disease
42. Beta blockade during and after myocardial infarction: An overview of the randomized trials
43. Confounding and misclassification
44. Quantifying heterogeneity in a meta-analysis